Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (15 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Medical Stock Q2 Earnings Due on Aug 1: ESRX, DVA & HUM

Solid R&D prospects likely to drive the healthcare industry in Q2 earnings.

    DVA vs. CHE: Which Stock Should Value Investors Buy Now?

    DVA vs. CHE: Which Stock Is the Better Value Option?

      Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

      Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.

        Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?

        DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.

          Here's Why You Should Invest in DaVIta (DVA) Stock Right Now

          Strong fundamentals and solid international presence make DaVita (DVA) a lucrative pick.

            DVA vs. USPH: Which Stock Is the Better Value Option?

            DVA vs. USPH: Which Stock Is the Better Value Option?

              Outpatient & Home Healthcare Stock Outlook: Prospects Bright

              The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.

                Varian Medical (VAR) Q3 Earnings: Surprise in Store?

                Solid prospects in the Oncology segment is likely to boost Varian Medical's (VAR) top-line performance in the third quarter of fiscal 2018.

                  Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?

                  Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.

                    Nabaparna Bhattacharya headshot

                    Outpatient Market Gains on Social Awareness: 3 Stocks in Focus

                    Here we discuss how Medical Outpatient and home healthcare continue to create opportunities for investors keen on parking their money in the healthcare space.

                      Why Is DaVita (DVA) Up 5.6% Since Its Last Earnings Report?

                      DaVita (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Health Insurance Industry Outlook - May 2018

                        Higher medical enrollment, surging revenues, medical cost management and an increasing share of revenues from complementary services helped results.

                          DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?

                          Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.

                            Is DaVita (DVA) a Great Stock for Value Investors Right Now?

                            Let's put DaVita (DVA) stock into this equation and find out if it is a good choice for value-oriented investors right now.

                              DaVita (DVA) Beats Q4 Earnings Estimates, Misses Revenues

                              Impressive results from Kidney Care business drove DaVita (DVA) in Q4.

                                DaVita (DVA) to Report Q4 Earnings: What's in the Cards?

                                DaVita's (DVA) fourth-quarter results to hurt from lackluster revenues stemming from high debts and labor union hurdles.

                                  DaVita (DVA) Partners with Epic to Launch EHR for Patients

                                  DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.

                                    Quest Diagnostics, LabCorp Defend Lab Fee Suit Against HHS

                                    Quest Diagnostics (DGX) and LabCorp (LH) join forces to back a case slapped on HHS for unable to follow a congressional directive to devise a market-based laboratory payment system.

                                      CVS-Aetna Deal Leading a Wave of Change in Hospital Sector

                                      Increased consolidation is being witnessed in the hospital sector as a defense against invasion by new comers.

                                        Company News For Dec 7, 2017

                                        Companies In The News are: PLAY,OXM,HRB,DVA,UNH

                                          DaVita (DVA) Surges: Stock Moves 13.6% Higher

                                          DaVita (DVA) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes

                                            UnitedHealth to Buy DaVita Medical, Expands Optum Business

                                            UnitedHealth's (UNH) intention to buy DaVita Medical reflects its continuous effort to build up a vertically integrated business model

                                              Benjamin Rains headshot

                                              UnitedHealth Continues Healthcare Shakeup With DaVita Deal

                                              On Wednesday, only a few days after the CVS (CVS) and Aetna (AET) deal helped shine a light on the quickly changing healthcare industry, UnitedHealth Group (UNH) announced that it will buy a unit of DaVita Inc. (DVA) for nearly $5 billion.

                                                New Strong Sell Stocks for November 10th

                                                Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                                                  What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?

                                                  DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.